For example, administration of a CXCL10-neutralizing antibody following aCD3 treatment resulted in reduced CD8+ T cell infiltration into pancreatic islets and increased diabetes remission compared to aCD3 monotherapy in preclinical type 1 diabetes models [27]. This evidence concerns the gene CXCL10 and diabetes mellitus.